Evidence map›Paper›PMID 40132801›Full record

ArticleVox sanguinis2025

Reduction in cord blood graft potency due to processing delay can be prevented by trehalose supplementation.

Suria Jahan, Harinad B Maganti, Jaina Patel, Roya Pasha, Emily Doxtator, Javed K Manesia, Nicolas Pineault

Abstract read
In one paragraph

Article in Vox sanguinis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Suria JahanCanadian Blood Services, Innovation & Portfolio Management, Ottawa, Ontario, Canada.
Harinad B MagantiCanadian Blood Services, Innovation & Portfolio Management, Ottawa, Ontario, Canada.
Jaina PatelCanadian Blood Services, Innovation & Portfolio Management, Ottawa, Ontario, Canada.
Roya PashaCanadian Blood Services, Innovation & Portfolio Management, Ottawa, Ontario, Canada.
Emily DoxtatorCanadian Blood Services, Innovation & Portfolio Management, Ottawa, Ontario, Canada.
Javed K ManesiaCanadian Blood Services, Innovation & Portfolio Management, Ottawa, Ontario, Canada.
Nicolas PineaultCanadian Blood Services, Innovation & Portfolio Management, Ottawa, Ontario, Canada.ORCID https://orcid.org/0000-0002-0082-0944

Funding

CIHR RN210152Health Canada
6 · The paper itself

Abstract

BACKGROUND AND

objectivesMaximizing the potency of cord blood (CB) units (CBU) is a goal of all CB banks. Low transplant cell dose in CB transplantation is one of several contributors to the slower engraftment. Processing delays could also be at play because CBU can be stored at room temperature (RT) for up to 48 h before cryopreservation. We hypothesized that prolonged storage at RT reduces the potency and engraftment activities of CBU due to the loss of haematopoietic stem cells (HSCs) and progenitor cells. MATERIALS AND

methodsCBU were split in half, with one half processed shortly after collection and the other half after 40 h of storage at RT. Viabilities and potencies were compared post thaw, and engraftment activity was tested in xenotransplants. Bioinformatic analysis was carried out to identify pathways modulated by prolonged storage at RT.

resultsProlonged storage at RT reduced the viability of CB cells and potency of grafts based on in vitro and in vivo assays. Transcriptomic analyses revealed that paracrine factors released in CBU induce several changes in gene expression programmes in CD34+ cells. These included the activation of the senescence gene CDKN1B and down-regulation of cell cycle and autophagy genes. Supplementation of CBU with trehalose prevented the loss in cell viability and potency. The latter was associated with the restoration of autophagy and suppression of the senescence gene CDKN1B.

conclusionThese results stress the importance of rapid processing of CBU and support further investigations on trehalose as a natural supplement to protect CBU' potency during storage.

Indexed as

Blood PreservationCord Blood Stem Cell TransplantationCryopreservationFetal BloodTrehaloseAnimalsCell SurvivalGraft SurvivalHematopoietic Stem CellsHumansMiceTime FactorsTrehalosehaematopoietic stem cellspotencyprocessing delaystoragetrehaloseumbilical cord bloodviability

Identifiers

PMID40132801
PMCPMC12116034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.